Background. The global rise of carbapenem resistant Gram-negative bacteria such as carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant non-fermenting bacteria is alarming and become threats to patient as only a few drugs remain active (e.g. colistin). Cefiderocol (S-649266) is a novel parenteral siderophore cephalosporin with potent activity against a wide variety of Gram-negative pathogens including carbapenem-resistant strains. This study evaluated the in vitro activity of cefiderocol and comparator agents against clinical isolates collected from urinary track source from North America.
Background. Few options remain for treatment of infections caused by multi-drug resistant (MDR), carbapenemase-producing gram-negative pathogens. Cefiderocol (CFDC; Shionogi & Co. Ltd), is a novel parenteral siderophore cephalosporin that enters the bacterial cell through the iron-siderophore uptake system. Here we report on the in vitro activity of CFDC against a set of well-characterized MDR gram-negative isolates collected by the Centers for Disease Control and Prevention.
Methods. Minimum inhibitory concentrations (MIC) values for CFDC in iron-depleted cation-adjusted Mueller Hinton broth were determined using reference broth microdilution. Study isolates (n = 315) included Enterobacteriaceae (59%), Pseudomonas aeruginosa (19%), Acinetobacter baumannii (17%), Stenotrophomonas maltophilia (4%), and Burkholderia cepacia complex (1%). Of these, 229 (73%) were carbapenemase-producers including Ambler Class A-(37%), Class B-(29%) and Class D-type (29%) enzymes. The remaining isolates included 51 β-lactam-resistant isolates that were non-carbapenemase-producers, and 35 β-lactam-susceptible isolates. Results were interpreted using suggested CFDC breakpoints of Sensitive ≤4 μg/mL and Resistant ≥16 μg/mL.
Results. The majority of the isolates (90.8%) were categorized as CFDC susceptible; the percentage of isolates with a CFDC MIC ≤4 μg/mL among Enterobacteriaceae, P. aeruginosa, and A. baumannii was 87.5%, 100%, and 89%, respectively. Percentage of isolates with a CFDC MIC ≤4 μg/mL that harbored a carbapenemase of the Class A-, Class B-, and Class D-type was 91.8%, 74.8%, 98.0%, respectively. By applying suggested breakpoints, 12 isolates were categorized as intermediate and 17 as resistant. The resistant isolates included 11 NDM-, 2 OXA-23-and 4 KPC-positive organisms.
Conclusion. Cefiderocol showed potent activity against MDR gram-negative pathogens including Class A, B, and D carbapenemase-producing isolates. Of note, all P. aeruginosa, including Class B metallo-β-lactamase producers, were susceptible to CFDC.
Disclosures. All authors: No reported disclosures. Friday, October 6, 2017: 12:30 PM Background. Antibiotic resistance among Gram-negative bacterial pathogens is a serious public health threat underscored by a diminishing antibiotic development pipeline. This study evaluated the in vitro activity of two new β-lactam/β-lactamase inhibitors, C/T and CZA, against the problematic pathogens ESBL-producing Enterobacteriaceae and MDR P. aeruginosa.
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Methods. A convenience sample of 74 ESBL-producing Enterobacteriaceae and 32 MDR P. aeruginosa clinical isolates (1 per patient episode), collected between 2012 and 2017 from 2 academic medical centers in Boston and Philadelphia, was used. MDR was defined as non-susceptibility to ≥1 agent in at least 3 antibiotic classes. Phenotypic confirmation of ESBL isolates was conducted via double disk testing. MICs were determined by broth microdilution in at least duplicate, on separate days, as recommended by CLSI. Klebsiella pneumoniae ATCC 700603 was used as a quality control strain with each experiment. Interpretive criteria for C/T per CLSI were: ≤2 (susceptible) / 4 (intermediate) / ≥8 (resistant) mg/L (Enterobacteriaceae) and ≤4 (susceptible) / 8 (intermediate) / ≥16 (resistant) mg/L (P. aeruginosa). Interpretive criteria for CZA per FDA were: ≤8 (susceptible) / ≥16 mg/L (resistant) (all organisms).
Results. Culture sites for the total isolate collection consisted of urine (n = 62), sputum (n = 30), wounds (n = 9), blood (n = 3), and bone (n = 2). ESBL-producing Enterobacteriaceae included Escherichia coli (n = 60), Klebsiella spp. (n = 12), Enterobacter cloacae (n = 1), and Citrobacter freundii (n = 1). ESBL Enterobacteriaceae isolates were 97.3% and 100% susceptible to C/T and CZA, respectively. The corresponding MIC 50/90 values were 0.5/2 mg/L for C/T and 0.25/0.5 mg/L for CZA. MDR P. aeruginosa isolates were 90.6% and 96.9% susceptible to C/T and CZA, respectively. The corresponding MIC 50/90 values were 1/4 mg/L for C/T and 2/8 mg/L for CZA.
Conclusion. C/T and CZA, two recently approved β-lactam/β-lactamase inhibitor combinations, maintained reliable activity against a collection of 106 MDR isolates from 2 geographically diverse medical centers.
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